US regulatory status: approved. Molecular target: Cyclooxygenase.
- Target
- Cyclooxygenase
- Mechanism
- Cyclooxygenase inhibitor
pharma · Refractory Focal Onset Epilepsy · Early Parkinson’s Disease
Biohaven Bioscience Ireland
Biohaven Bioscience Ireland Limited
Biohaven Bioscience Ireland drug portfolio — 8 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
GB HQ
EMA registrant Type
Company details
- Status
- Public
- HQ
- GB
- Programs
- 7
- Drugs
- 8
- Patents
- 0
Biohaven Bioscience Ireland pipeline
Portfolio lens on 8 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Biohaven Bioscience Ireland drug portfolio — 8 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Biohaven Bioscience Ireland in public FDA and regional records.
-
ioflupane (123l)
Various (V09)Various (V09) compound in Biohaven Bioscience Ireland's portfolio. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
US regulatory status: approved. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
Development asset linked to Biohaven Bioscience Ireland in public FDA and regional records.
-
Development asset linked to Biohaven Bioscience Ireland in public FDA and regional records.
-
Development asset linked to Biohaven Bioscience Ireland in public FDA and regional records.
-
Development asset linked to Biohaven Bioscience Ireland in public FDA and regional records.